Pharmafile Logo
Pharmafocus logo
Advanced Search

Xgeva

Showing 9 posts of 9 posts found.

amgen_flag

FDA clears Amgen’s bone drug for multiple myeloma

January 8, 2018
Sales and Marketing Amgen, Cancer, Xgeva, multiple myeloma, pharma

Amgen has announced that the FDA has approved the indication expansion of its drug Xgeva (denosumab) to include the treatment …

News
amgen_flag

Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study

June 21, 2016
Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics

US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …

News
Amgen image

Amgen files high earnings for Q1

April 22, 2015
Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis

Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …

News
Prolia image

ABPI worried about Prolia use

March 10, 2014
Sales and Marketing ABPI, Amgen, NHS, Xgeva

The ABPI has once again voiced concern that NHS patients in some areas of England are not getting access to …

News
Xgeva image

Xgeva gains NICE recommendation for bone metastasis

August 17, 2012
Sales and Marketing Amgen, NICE, Xgeva, bone metastatis

NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News

Amgen bone cancer drug Xgeva approved in Europe

July 18, 2011
Sales and Marketing Amgen, Prolia, Xgeva, denosumab

Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …

News

CHMP roundup

May 24, 2011
Sales and Marketing CHMP, EMA, Fampyra, Vibativ, Victrelis, Xgeva, Yervoy

The latest products to be recommended for European approval include MSD’s Victrelis, Astellas Pharma Europe’s Vibativ, Amgen Europe’s Xgeva and …

News

Denosumab approved for bone cancer use

November 19, 2010
Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab

Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …

News
The Gateway to Local Adoption Series

Latest content

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026

Rare diseases – spinal muscular atrophy

January 30, 2026

Could targeting the molecular causes of infertility finally transform IVF success rates?

January 29, 2026

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026

Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building

January 29, 2026